Literature DB >> 20657547

Radiotherapy: Radioactive somatostatin analog therapy against carcinoids.

Run Yu.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20657547     DOI： 10.1038/nrendo.2010.94

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

Review 1.  Revisiting C.G. Moertel's land of small tumors.

Authors:  Larry K Kvols
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

2.  90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Authors:  David L Bushnell; Thomas M O'Dorisio; M Sue O'Dorisio; Yusuf Menda; Rodney J Hicks; Eric Van Cutsem; Jean-Louis Baulieu; Francoise Borson-Chazot; Lowell Anthony; Al B Benson; Kjell Oberg; Ashley B Grossman; Mary Connolly; Hakim Bouterfa; Yong Li; Katherine A Kacena; Norman LaFrance; Stanislas A Pauwels
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

Review 3.  Interferon in the management of neuroendocrine GEP-tumors: a review.

Authors:  K Oberg
Journal:  Digestion       Date:  2000       Impact factor: 3.216

4.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

5.  Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors.

Authors:  Ebrahim S Delpassand; Jennifer Sims-Mourtada; Hitomi Saso; Ali Azhdarinia; Faramarz Ashoori; Farzad Torabi; Gregory Espenan; Warren H Moore; Eugene Woltering; Lowell Anthony
Journal:  Cancer Biother Radiopharm       Date:  2008-06       Impact factor: 3.099

Review 6.  Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.

Authors:  Martijn Van Essen; Eric P Krenning; Marion De Jong; Roelf Valkema; Dik J Kwekkeboom
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

7.  Carcinoid case presentation and discussion: the American perspective.

Authors:  R R P Warner
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

Review 8.  Progress in the treatment of neuroendocrine tumors.

Authors:  Jennifer A Chan; Matthew H Kulke
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

9.  Neuroendocrine tumors: novel approaches in the age of targeted therapy.

Authors:  Alexandria T Phan; James C Yao
Journal:  Oncology (Williston Park)       Date:  2008-12       Impact factor: 2.990
  9 in total
  2 in total

Review 1.  Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment.

Authors:  Cynthia Ro; Wanxing Chai; Victoria E Yu; Run Yu
Journal:  Chin J Cancer       Date:  2012-12-14

Review 2.  Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.

Authors:  Martine Bocchini; Fabio Nicolini; Stefano Severi; Alberto Bongiovanni; Toni Ibrahim; Giorgia Simonetti; Ilaria Grassi; Massimiliano Mazza
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.